BIBLIOGRAFIA

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: The
Framingham study. Ann Intern Med 1976; 85: 447-452.

2. Parrish HM, Carr LA, Hall DG y Cols. Time interval from castration in premenopausal women to development of excessive
coronary atherosclerosis. Amer J Obst Gynecol 1967; 99: 155-162.

3. Aitken JM, Hart DM, Anderson JB y Cols. Osteoporosis after oophorectomy for non-malignant disease in premenopausal
women. Brit Med J 1973; 2: 325-328.

4. Richeson LS, Wahner HW, Melton LJ, III y Cols. Relative contributions of aging and estrogen deficiency to
postmenopausal bone loss. N Eng J Med 1984; 311: 1273-1275.

5. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Eng J Med 1993; 329: 247-256.

6. Lerner DJ, Kannel WB. Patterns in coronary heart disease - Morbidity and mortality in the sexes: A 26-year follow-up of
the Framingham population. Amer Heart J 1986; 111: 383-390.

7. Peck WA, Riggs BL, Bell NH y Cols. Research directions in osteoporosis. Amer J Med 1988; 84: 275-282.

8. Lindsay R, Aitken JM, Anderson JB. Long-term prevention of post-menopausal osteoporosis by estrogen. Lancet 1976; 1:
1038-1041.

9. Compston JE. HRT and osteoporosis. Brit Med Bull 1992; 48: 309-344.

10. Quigley MET, Martin PL, Burnir AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Amer J Obst
Gynecol 1987; 156: 1516-1523.

11. Munk-Jensen N, Pors Nielsen S, Obel EB, Eriksen PB. Reversal of postmenopausal vertebral bone loss by estrogen and
progestogen: A double blind, placebo-controlled study. Brit Med J 1988; 296: 1150-1152.

12. Felson DT, Zhang Y, Hannan MT, Xiel DP, Wilson PWF, Andersen JJ. The effect of postmenopausal estrogen therapy on
bone density in elderly women. N Eng Med J 1993; 329: 1141-1146.

13. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Amer J Med 1990; 90: 107-110.

14. Furuhjelm M, Fedor-Freybergh, P. The influence of estrogens on the psyche in climacteric and post-menopausal women.
En: Consensus on Menopause Research- Van Keep PA, Greenblatt RB, Albeaux-Fernet MM. (Eds.). University Park Press,
Baltimore 1976; 84-93.

15. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women.
Psychoneuroendocrinology 1988; 13: 345-357.

16. Sherwin BB. Estrogen and Memory in Postmenopausal Women. Third Annual Meeting. North American Menopause
Society 1992; 50.

17. Honjo H, Tanaka H, Kashiwagi T, Urabe M, Okada H, Hayashi M, Hayashi K. Senile dementia-Alzheimer's type and
estrogen. Hormone Metab Res 1995; 27: 204-207.

18. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA - J
Am Med Assn 1993; 269: 2637-2641.

19. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA - J Am Med Assn 1991; 265:
1861-1867.

20. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary disease: A quantitative assessment of the
epidemiological evidence. Prev Med 1991; 20: 47-63.

21. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger D, Ernster UL, Cummings SR. Hormone therapy to prevent
disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.

22. Posthuma WFM, Westendorp RGJ, Vandenbrouke JP. Cardioprotective effect of hormone replacement therapy in
postmenopausal women: ls the evidence biased? Brit Med J 1994; 308: 1268-1269.

23. Stevenson JC, Baum M. Hormone replacement therapy. Brit Med J 1994; 309: 191.

24. Kirchstein R. From the National Institutes of Health: Largest US clinical trial ever gets underway. JAMA - J Am Med Assn
1993; 270: 1521.

25. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in
postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA - J Am Med Assn 1995;
273: 199-208.

26. Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. Amer Heart J 1994; 128: 1337-1343.

27. Punnonen RH, Jokela HA, Dastidar PS, Nevala M, Laippala, PJ. Combined oestrogen-progestin replacement therapy
prevents atherosclerosis in postmenopausal women. Maturitas 1995; 21: 179-187.

28. Barrett-Connor E. Hormone replacement and cancer Brit Med Bull 1992; 48: 345-355.

29. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestogen supplementation of exagenous estrogens
and risk of endometrial cancer Lancet 1991; 338: 274-277.

30. Hunt K, Vessey M. Mortality from cancer and cardiovascular disease and hormonal substitution therapy. Prog Reproduct
Biol Med 1989; 13: 63-71.

31. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int
J Cancer 1988; 42: 832-888.

32. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy. II. A prospective study in the
relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-79.

33. Colditz GA, Hankinson SE, Hunter, DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The
use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995; 332:
1589-1593.

34. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: A survey of women's knowledge and altitudes. Arch
Intern Med 1989; 149: 133-136.

35. Prough SG, Aksel S, Wiebe RH y Cols. Continuous estrogen/progestin therapy in menopause. Amer J Obst Gynecol
1987; 157: 1449-1453.

36. Hammond CB. Women's Concerns with hormone replacement therapy - Compliance issues. Fert Steril 1994; 62:
157S-160S.

37. Ravnikar VA. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone
replacement therapy preventative health benefits? Women's Health Issues 1992; 2: 75-82.

38. Rosenberg L. Hormone replacement therapy: The need for reconsideration. Amer J Public Health 1993; 83: 1670-1673.

39. Bell L. Change of heart. Dallas Morning News 1995; Feb 7: 6D.

40. Furr BJA, Jordan VC. The pharmacology and clinical use of tamoxifen. Pharmacol Ther 1984; 25: 127-205.

41. Sato M, Glasebrook AL, Bryant HU. Raloxifene: A selective estrogen receptor modulator. J Bone Miner Metab 1995; 12
(Suppl. 2): S9-S20.

42. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or
immune therapy. Lancet 1992; 339: 71-85.

43. Gotfredsen R, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in pre-menopausal women with
breast cancer. Cancer 1984; 53: 853-857.

44. Sismondi P, Biglia N, Giai M, Sgro L, Campagnoli C. Metabolic effects of tamoxifen in postmenopause- Anticancer Res
1994; 14: 2237-2244.

45. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial- Brit Med J 1991; 303:
435-437.

46. Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast
cancer in a randomized trial of adjuvant tamoxifen. J Nat Cancer Inst 1993; 85: 1398-1406.

47. Fisher B, Constatino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated
breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project. J Nat Cancer Inst 1994; 86:
527-537.

48. Ross D, Whitehead M. Hormonal manipulation and gynecological cancer: The tamoxifen dilemma- Curr Opin Obst
Gynecol 1995; 7: 63-68.

49. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor Cell 1987;
51: 941-951.

50. Webster NJ, Green S, Jin JR, Chambon P. The hormone binding domains of the estrogen and glucocorticoid receptors
contain an inducible transcription activating function. Cell 1988; 54: 199-207.

51. Berry M, Metzger D, Chambon P. Role of the two activating domains of the estrogen receptor in the cell-type and
promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 1990; 9: 2811-2818.

52. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen
receptor transactional capacity is determined by both cellular and promotor context and mediated by two functionally distinct
intramolecular regions. Mol Endocrinol 1994; 8: 21-30.

53. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals
three distinct classes of antiestrogens. Mol Endocrinol 1995; 9: 659-669.

54. Umayahara Y, Kawamori R, Watada H, Imano E, Iwarna N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T.
Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer J Biol Chem 1994; 269:
16433-16442.

55. Webb P, López GN, Uht RM, Kishner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin
for the cell-specific estrogen-like effects of antiestrogens- Mol Endocrinol 1995; 9: 443-456.

56. Cypriani B, Tabacik C, Descomps B. Effect of estradiol and antiestrogens on cholesterol biosynthesis in
hormone-dependent and -independent breast cancer cell lines. Biochim Biophys Acta 1988; 972: 167-178.

57. Gylling H, Mantyla E, Miettinen TA. Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis.
Atherosclerosis 1992; 96: 245-247.

58. Blac LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci
1983; 32: 1031-1036.

59. Wakeling AE, Valcaccia B, Newboult E. y Cols. Non-steroidal antiestrogens Receptor binding and biological response in
rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984; 20: 111-120.

60. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of
carcinogen-induced mammary turmos and on LH and prolactin levels. Life Sci 1983; 32: 2869-2875.

61. Gottardis NM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat
mammary carcinoma model. Cancer Res 1987; 47: 4020-4024.

62. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA. Antiestrogens 2.
Structure-activity studies in a series of 3-aroyl-2-arylbenzo [b] thiophene derivatives leading to
[6-hydroxy-2-(4-hydroxyphenyl) benzo [b] thien-3-yl] [4- [2-(1-piperidinyl) ethoxy] phenyl] methanone hydrochloride
(LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity J Med Chem 1984; 27:
1057-1066.

63. Fuchs-Young R, Magee DE, Cole HW, Short L, Glasebrook AL, Rippy MK, Termine JD, Bryant HU. Raloxifene is a
tissue specific anti-estrogen that blocks tamoxifen or estrogen-stimulated uterotrophic effects. Endocrinology 1995; 136
(Suppl.): 57.

64. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan DJ, Bendele R, Kauffman RF, Bensch WR,
Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without
causing uterino hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-69.

65. Evans G, Bryant HU, Magee D, Sato M, Turner RT. - The effects of raloxifene on tibia histomorphometry in
ovariectomized rats. Endocrinology 1993; 134: 2283-2288.

66. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology
1994; 135: 2001-2005.

67. Brown MS, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980; 254: 11360-11366.

68. Ma PTS, Yamamoto T, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptor in livers of
rabbits treated with 17-ethinyl estradiol. Proc Nat Acad Sci USA 1986; 83: 792-796.

69. Draper MW, Flowers DE, Huster WJ y Cols. Effects of raloxifene (LY139481) on biochemical markers of bone and lipid
metabolism in healthy postmenopausal women. En: Proceedings of the Fourth International Symposium on Osteoporosis and
Consensus Development Conference, 1993. C. Christiansen and B. Riis (Eds.). Handelstrykkeriet Aalborg Aps, Aalborg,
Denmark 1993; 119-121.

70. Yang NN, Hardiker S. Estrogen receptor: Two ligands, two transcription pathways. J Bone Miner Res 1994; 9(Suppl- 1):
S144.

71. Wilson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR,
Triantafillou JA, Wolfe SG, Baer PG. 3-[4-(1,2-Diphenylbut-1-enyl) phenyl]acrylic acid: A non-steroidal estrogen with
functional selectivity for bone over uterus in rats. J Med Chem 1994; 37: 1550-1552.

72. Ke HZ, Chen HK, Simmons HA, Pirie CM, Ma YF, Jee WS, Thompson DD. Droloxifene, a new estrogen agonist,
prevents ovariectomy-induced bono loss in growing and aged female rats. Endocrinology 1995; 136: 2435-2441.

73. Coombes RC, Haynes BC, Dousett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, Mccaque R, Jarman M.
Idoxifene: Report of a phase I study with patients with metastatic breast cancer. Cancer Res 1995; 55: 1070-1074.

74. Honesty HD, Shemana I, Gams, RA, Herry DS y Cols. Anti-estrogenic potency of toremifene and tamoxifen in
post-menopausal women. A. J Clin Oncol 1993; 16: 117-122.

75. Gallagher A, Chambers TJ, Tobias JH. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female
rats. Endocrinology 1993; 133: 2787-2791.

76. Washburn SA, Adams MR, Clarkson TB, Adelman SJ. A conjugated equinoestrogen with differential effects on uterine
weight and plasma cholesterol in the rat. A. J Obst Gynecol 1993; 169: 251-256.